



10-Hydroxydec-2-Enoic Acid Reduces Hydroxyl Free Radical-Induced Damage to Vascular Smooth Muscle Cells by Rescuing Protein and Energy Metabolism

OPEN ACCESS

Edited by:

A. M. Abd El-Aty,
Cairo University, Egypt

Reviewed by:

Siavash Shahbazi Nia,
Texas Tech University Health Sciences
Center, United States
Shanmuga Sundaram Mahalingam,
Case Western Reserve University,
United States
Umakant Sahu,
Northwestern University,
United States

*Correspondence:

Lu Zhang
zhanglu@haut.edu.cn
Bin Han
hanbin@caas.cn
Jianke Li
apislijk@126.com

Specialty section:

This article was submitted to
Food Chemistry,
a section of the journal
Frontiers in Nutrition

Received: 11 February 2022

Accepted: 08 April 2022

Published: 26 May 2022

Citation:

Fan P, Sha F, Ma C, Wei Q, Zhou Y,
Shi J, Fu J, Zhang L, Han B and Li J
(2022) 10-Hydroxydec-2-Enoic Acid
Reduces Hydroxyl Free
Radical-Induced Damage to Vascular
Smooth Muscle Cells by Rescuing
Protein and Energy Metabolism.
Front. Nutr. 9:873892.
doi: 10.3389/fnut.2022.873892

Pei Fan^{1,2}, Fangfang Sha², Chuan Ma¹, Qiaohong Wei¹, Yaqi Zhou², Jing Shi²,
Jiaojiao Fu², Lu Zhang^{2*}, Bin Han^{1*} and Jianke Li^{1*}

¹ Institute of Apicultural Research/Key Laboratory of Pollinating Insect Biology, Ministry of Agriculture and Rural Affairs, Chinese Academy of Agricultural Sciences, Beijing, China, ² College of Biological Engineering, Henan University of Technology, Zhengzhou, China

10-Hydroxydec-2-enoic acid (10-HDA), an unsaturated hydroxyl fatty acid from the natural food royal jelly, can protect against cell and tissue damage, yet the underlying mechanisms are still unexplored. We hypothesized that the neutralization of the hydroxyl free radical ($\bullet\text{OH}$), the most reactive oxygen species, is an important factor underlying the cytoprotective effect of 10-HDA. In this study, we found that the $\bullet\text{OH}$ scavenging rate by 10-HDA (2%, g/ml) was more than 20%, which was achieved through multiple-step oxidization of the $-\text{OH}$ group and $\text{C}=\text{C}$ bond of 10-HDA. Moreover, 10-HDA significantly enhanced the viability of vascular smooth muscle cells (VSMCs) damaged by $\bullet\text{OH}$ ($P < 0.01$), significantly attenuated $\bullet\text{OH}$ -derived malondialdehyde production that represents cellular lipid peroxidation ($P < 0.05$), and significantly increased the glutathione levels in $\bullet\text{OH}$ -stressed VSMCs ($P < 0.05$), indicating the role of 10-HDA in reducing $\bullet\text{OH}$ -induced cytotoxicity. Further proteomic analyses of VSMCs identified 195 proteins with decreased expression by $\bullet\text{OH}$ challenge that were upregulated by 10-HDA rescue and were primarily involved in protein synthesis (such as translation, protein transport, ribosome, and RNA binding) and energy metabolism (such as fatty acid degradation and glycolysis/gluconeogenesis). Taken together, these findings indicate that 10-HDA can effectively promote cell survival by antagonizing $\bullet\text{OH}$ -induced injury in VSMCs. To the best of our knowledge, our results provide the first concrete evidence that 10-HDA-scavenged $\bullet\text{OH}$ could be a potential pharmacological application for maintaining vascular health.

Keywords: royal jelly, 10-hydroxydec-2-enoic acid, hydroxyl radical, vascular smooth muscle cell, proteomics

INTRODUCTION

Royal jelly (RJ), a secretion from the hypopharyngeal and mandibular glands of worker honeybees, has been widely regarded as a functional food for the promotion of human health (1). Among the components of RJ, 10-hydroxydec-2-enoic acid (10-HDA) is a unique substance exclusively found in RJ at a concentration of 1.4–2.0% (2). Accumulating evidence suggests that 10-HDA has a wide range of bioactivities, including antibacterial, anti-inflammatory, and antitumor effects (3–6). Furthermore, 10-HDA has been shown to prevent cell and tissue photoaging damage induced by ultraviolet irradiation by enhancing collagen production in human dermal fibroblasts (7). 10-HDA also alleviated lipopolysaccharide (LPS)-induced blood–brain barrier damage in mice (8). Our previous work established that 10-HDA attenuated cyclophosphamide-induced weight loss in the mouse thymus and spleen and thus has the potential to fortify immunity (9). Although the emerging roles of 10-HDA against cell damage have been demonstrated in different cell types, the molecular mechanisms still remain largely unknown.

Oxygen free radicals, such as the hydroxyl radical (\bullet OH) and superoxide anion radical ($O_2\bullet^-$), are major reactive oxygen species (ROS). ROS are involved in a variety of cell processes and diseases and are highly reactive (10). ROS can also damage DNA, proteins, and lipids. In particular, the cell membrane is susceptible to ROS attack and lipid peroxidation, which impairs cellular structures and functions (11). The alkylating agent and chemotherapeutic cyclophosphamide can be metabolized into acrolein, a substance that can produce a large quantity of ROS (12). Therefore, our previous data in which 10-HDA was found to mitigate immune organ damage caused by cyclophosphamide may potentially result from the role of 10-HDA in removing ROS (9). Among all the oxygen free radicals, \bullet OH is the most potent and non-selective, and it is generated in a number of conditions *in vivo* in which it can trigger severe cell damage (13–15). Hence, we hypothesized that \bullet OH scavenging by 10-HDA could be the reason for the reduction of cell damage caused by cyclophosphamide.

Cardiovascular disease is one of the greatest risks to human health worldwide. Vascular smooth muscle cells (VSMCs) are the major cells in the blood vessel wall, controlling vascular movement *via* contraction and relaxation. Dysfunction of VSMCs leads to delayed development of blood vessels and thus may cause embryonic and post-natal abnormalities (16), reflecting the fact that VSMC survival is directly linked to vascular health. Oxidative stress of VSMCs resulting from high ROS levels has been associated with cardiovascular diseases, including atherosclerosis, hypertension, and stenosis (17). However, different ROS exert distinct effects on VSMCs, in which \bullet OH, but not $O_2\bullet^-$, causes the death of VSMCs (18, 19), making VSMCs an appropriate model for investigating specific ROS-induced cell damage. Several substances, such as gallic acid, induced VSMC death *via* the generation of \bullet OH (19). Therefore, in this study, the capability of 10-HDA to scavenge \bullet OH was tested first using the Fenton system, commonly used to investigate ROS-induced cell impairment *in vitro*, in which

\bullet OH is produced by Fe^{2+} and H_2O_2 (15). Then, a model of \bullet OH-damaged VSMCs was established to uncover the underlying mechanisms of 10-HDA in survival protection, casting light on the potential of 10-HDA as a new agent for retaining vascular health.

MATERIALS AND METHODS

Major Chemicals and Materials

The major chemicals and materials are specified in the following sections.

Measurement of the Scavenging Rate of \bullet OH by 10-HDA

To determine the role of 10-HDA in \bullet OH removal, the Hydroxyl Free Radical Scavenging Capacity Assay Kit (Catalog No. R30345, Yuanye Bio Sci & Tech Co., Ltd, Shanghai, China), based on the Fenton/1,10-phenanthroline monohydrate colorimetric method, and the Hydroxyl Free Radical Assay Kit (Catalog No. A018-1-1, Nanjing Jiancheng Bioengineering Institute, Nanjing, China), based on the Fenton/Griess reagent method, were used to measure the scavenging rate of \bullet OH. In brief, 0.02 g 10-HDA (Yuanye Bio Sci & Tech Co., Ltd., Shanghai, China) was dissolved in 200 μ l ethanol, followed by the addition of 800 μ l distilled water, to a final concentration of 2% (g/ml) 10-HDA, which approximates its concentration in RJ. Then, 400 μ l of the 10-HDA solution was added to the kit reaction system, and the solution absorbance, which was later used to calculate the scavenging rate of \bullet OH, was assayed at the wavelength of 536 nm *via* a visible spectrophotometer (Shanghai Metash Instrument Co., Ltd., Shanghai, China). A 400 μ l sample of solution without adding 10-HDA was prepared as the control sample. A sample containing 0.02 g (1,000 IU/g) vitamin E (Beijing Solarbio Science & Technology Co., Ltd., Beijing, China) was used as a positive control.

Product Identification From \bullet OH and 10-HDA Reactions

To gain more evidence of 10-HDA removal of \bullet OH, high-performance liquid chromatography (HPLC) was used to trace concentration changes after adding \bullet OH to the 10-HDA solution, which is a direct observation of 10-HDA reacting with \bullet OH. The reaction system (i.e., 10-HDA + \bullet OH sample) (10 ml), containing 0.2 g 10-HDA, 2 ml ethanol, 0.033 g $FeSO_4\bullet 7H_2O$, and 3.3 ml H_2O_2 , was incubated at 37°C for 3 h. For the 10-HDA control sample (10-HDA sample) (10 ml), H_2O_2 was substituted with the same volume of H_2O . Both samples were diluted with ethanol at a 1:1 ratio prior to the analysis. The HPLC analysis was performed using a Waters e2695 platform (Waters Corp., Milford, MA, USA) with a C18 column (5 μ m, 4.6 mm \times 250 mm) (TupLabs, Tianjin, China), in which the mobile phase was methanol and 0.1% formic acid (55:45, v/v), the flow rate was 0.5 ml/min at room temperature, and the detection wavelength was 210 nm for 10-HDA, as reported in a previous study (20).

Qualitative Analysis of the Products of 10-HDA Reacted With •OH

To characterize the products from the reaction between 10-HDA and •OH, the 10-HDA sample and the 10-HDA + •OH sample (3 μ l each), both of which were prepared as described in the “Product identification from •OH and 10-HDA reactions” section, were assayed *via* ultra-HPLC-high-resolution mass spectrometry (UHPLC-HRMS) as previously described (21). In brief, the liquid chromatographic separation was performed on a Dionex UltiMate 3000 system (Thermo Fisher Scientific, Inc., Waltham, MA, USA) using reverse-phase liquid chromatography (RPLC) with a positive/negative polarity switching mode. The RPLC separation was conducted on a ZORBAX SB-Aq C18 column (100 mm \times 2.1 mm, 1.8 μ m; Agilent Technology) at 40°C with mobile phase A (i.e., 0.1% formic acid in water) and B (i.e., 0.1% formic acid in acetonitrile). Gradient elution with a flow rate of 0.3 ml/min was set as follows: 0–2 min, 95–70% A; 2–8 min, 70–15% A; 8–9 min, 15–15% A; 9–9.5 min, 15–95% A; and 9.5–13 min, 95–95% A. A Q-Exactive mass spectrometer (MS) (Thermo Fisher Scientific, Inc., Waltham, MA, USA) equipped with a heated electrospray ionization source was employed for MS analysis. The raw data were analyzed with the Qual Browser in the Xcalibur software (version 4.0, Thermo Fisher Scientific, Inc., Waltham, MA, USA), in which the mass tolerance was set to 5.0 ppm, the scan filter settings were FTMS-p ESI FULL ms, and the plot type was selected as base peak.

Cell Culture

Mouse VSMCs (an immortalized C57BL/6 strain) were purchased from American Type Culture Collection. The cells were cultured in the Dulbecco’s modified Eagle’s medium (Gibco, Thermo Fisher Scientific, Inc., Waltham, MA, USA) with 10% fetal bovine serum at 37°C and 5% CO₂ (Zhejiang Tianhang Biotechnology Co., Ltd, Huzhou, Zhejiang, China).

VSMC Viability Comparison by Morphological Imaging and 3-(4,5-Dimethylthiazol-2-Yl)-2,5-Diphenyltetrazolium Bromide Assay

To investigate the role of 10-HDA in protecting against •OH-induced cytotoxicity, the VSMCs were subjected to a Fenton reaction system to generate •OH damage. For the Fenton reaction system, FeSO₄•7H₂O and H₂O₂ were added to the VSMC culture media to final concentrations of 0.1 mM and 1 mM, respectively, to expose the cells to •OH. To analyze the protective effects of 10-HDA on VSMCs, the cells were treated with 10-HDA prior to the •OH exposure, based on previously reported methods with some modifications (5, 22). In brief, VSMC media were supplemented with 10-HDA dissolved in ethanol (i.e., 3 mM) for 30 min prior to the addition of the Fenton system. Importantly, to account for the potential adverse effects of ethanol on cells and 10-HDA’s ability to reduce media pH, the control and the •OH-damaged VSMCs were also treated with the same volume of ethanol, and the pH of the media

was adjusted to that of the 10-HDA-supplemented VSMCs using HCl. Thereafter, all three groups of VSMCs (i.e., control, •OH-damaged, and 10-HDA-supplemented) were incubated at 37°C for 3 h.

To determine whether 10-HDA attenuates •OH-induced VSMC damage, the morphologies of the control, •OH-damaged, and 10-HDA-supplemented VSMCs were imaged and compared. First, VSMCs (5 \times 10⁵ cells/well) were seeded in a 6-well plate and cultured for 24 h. After treatment of •OH or •OH + 10-HDA at 37°C for 3 h in 2 ml media, the three groups of VSMCs were photographed under an inverted microscope using a 10 \times 40 magnification.

To further investigate 10-HDA’s ability to reduce VSMC damage by •OH, the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (Beijing Solarbio Science & Technology Co., Ltd., Beijing, China) was used to compare the viability of the VSMCs. VSMCs were seeded in a 96-well plate (5 \times 10³ cells/well). After 24 h, the media were replaced by 100 μ l fresh media that contained treatment of •OH or •OH + 10-HDA. After incubation at 37°C for 3 h, 20 μ l MTT (5 mg/ml) was added to each well, and the cells were incubated for another 4 h. Finally, the cells were gently shaken with 100 μ l dimethyl sulfoxide for 15 min in the dark. The absorbance of each well was assayed at 490 nm *via* a microplate reader (Tecan Group Ltd., Männedorf, Switzerland).

Cell Lipid Peroxidation Assay Through Malondialdehyde Determination

To elucidate the mechanism of how 10-HDA restores the viability of •OH-damaged VSMCs, the levels of cell lipid peroxidation, usually reflected by MDA production, were measured. The VSMCs were seeded in a 24-well plate at 1 \times 10⁵ cells/well and cultured for 24 h. The cells were then treated with •OH or •OH + 10-HDA at 37°C for 3 h. Furthermore, 10 μ l of the cell supernatant was used to determine the MDA level using an MDA assay kit (Catalog No. R21870, Yuanye Bio Sci & Tech Co., Ltd., Shanghai, China). After the reaction, the absorbance was assayed at 535 nm to calculate MDA concentration, according to the kit manufacturer’s instructions. The MDA level in the lysate of the VSMCs was also determined by using a 6-well plate with 3 \times 10⁵ cells/well, with the same •OH or •OH + 10-HDA treatment, and the same assay kit.

Glutathione (Reduced) Assay in VSMCs

To evaluate the effects of 10-HDA against oxidative stress from •OH, the levels of reduced glutathione, an endogenous antioxidant in VSMCs, were determined. VSMCs were seeded at 3 \times 10⁵ cells/well in a 6-well plate and then treated with •OH or •OH + 10-HDA, using the same treatment as described in the “VSMC viability comparison by morphological imaging and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay” section. The reduced glutathione contents in VSMCs were measured using the Reduced Glutathione Assay Kit (Catalog No. BC1175, Beijing Solarbio Science & Technology Co., Ltd., Beijing, China).

Proteomic Analysis of VSMCs With •OH Cytotoxicity and 10-HDA Rescue

To explore the mechanisms of 10-HDA protection against •OH toxicity, a liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based proteomic strategy was applied. The control, •OH-damaged, and 10-HDA-rescued VSMCs were obtained according to the method described in the “VSMC viability comparison by morphological imaging and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay” section. For each group, three replicates of cell samples were prepared.

To extract protein, the VSMCs were homogenized in lysis buffer at a cell:lysis buffer ratio of 1:10 (mg/μl) (23) and ultrasonicated on ice. After centrifugation at 12,000 rpm for 15 min, the supernatant was collected. Furthermore, three times the supernatant volume of ice-cold acetone was added, and the sample was incubated for 30 min to precipitate the proteins, which were then isolated by centrifugation at 8,000 rpm for 15 min. The proteins were dried for 10 min to remove the acetone, redissolved in 80 μl urea (5 M), and mixed with 320 μl NH₄HCO₃ (40 mM). The protein concentration was assayed *via* the Bradford method. Next, 200 μg protein samples were reduced using dithiothreitol (DTT) (100 mM) at the ratio of 10:1 (v/v) protein solution: DTT for 1 h at room temperature, followed by alkylation in iodoacetamide (100 mM) in the dark for 1 h using five times the volume of DTT. Samples were then digested at 37°C for 12 h to prepare peptides using 4 μg sequencing grade-modified trypsin (Promega Corporation, Madison, WI, USA). The trypsinization was terminated using 1 μl formic acid. The peptides were desalted using C18 columns (Thermo Fisher Scientific, Inc., Waltham, MA, USA) and dried *via* a rotary evaporator. Finally, the peptides were redissolved in 0.1% formic acid at a concentration of 0.25 μg/μl.

Digested samples (8 μl) were analyzed in a Q-Exactive HF MS (Thermo Fisher Scientific, Inc., Waltham, MA, USA), using the same parameters for the HPLC and MS as previously reported (24). The raw data retrieved from the Xcalibur software (version 4.0, Thermo Fisher Scientific, Inc., Waltham, MA, USA) were searched using the PEAKS software (version 8.5, Bioinformatics Solutions Inc., Waterloo, ON, Canada) against a database containing 86,618 protein sequences of *Mus musculus* from Uniprot (<https://www.uniprot.org>) released in January 2021 and the common Repository of Adventitious Proteins (cRAP, downloaded from The Global Proteome Machine Organization). Protein abundance was determined by label-free quantification (LFQ) between groups, in which the protein peptides screened for LFQ contained at least two unique peptides, with at least two samples per group. The protein fold change was set to ≥ 1.5 with a significance of ≥ 13 . The significance method used was the analysis of variance (ANOVA). The differentially expressed proteins were identified in protein groups.

Bioinformatical Analysis

To interpret the molecular basis of 10-HDA in relieving the •OH-damaged VSMC malfunction at the protein level, the proteins that were significantly downregulated by •OH and

significantly upregulated with the 10-HDA treatment were used for the enrichment analysis with Gene Ontology (GO) for GO terms and the Kyoto Encyclopedia of Genes and Genomes (KEGG) for pathways through the online tool KOBAS-i (kobas.cbi.pku.edu.cn) (25). The Uniprot IDs for the proteins were analyzed using the hypergeometric test/Fisher's exact test as the statistical method, and the false discovery rate was corrected by the Benjamini and Hochberg procedure. The term or pathway with a corrected *P*-value < 0.05 was considered significant.

To expound on the relationships between key proteins that might be regulated by 10-HDA in the •OH-damaged VSMCs, the protein-protein interaction (PPI) networks for these proteins were constructed using the online software NetworkAnalyst 3.0 (www.networkanalyst.ca) (updated 2021-05-18) (26). In brief, the generic PPI networks were generated based on the STRING Interactome with medium (400)-high (1,000) confidence scores (the score cutoff was set as 900). The subnetworks that had at least three nodes were shown.


To interpret the distribution of proteins downregulated by •OH and upregulated by 10-HDA in VSMCs, the online tool Cell-PLoc 2.0 (www.csbio.sjtu.edu.cn/bioinf/Cell-PLoc-2) was used to predict the protein subcellular localization (27). The amino acid sequences of the proteins were downloaded from the UniProt database and analyzed in Euk-mPLoc 2.0, a sub-module in Cell-PLoc 2.0, for the prediction of eukaryotic proteins.

Intracellular Adenosine-Triphosphate Assay of VSMCs

To determine whether 10-HDA boosts energy production when exposed to •OH oxidative stress in VSMCs, the intracellular ATP levels of the control, •OH-damaged, and •OH + 10-HDA-supplemented VSMCs were assayed and compared. The VSMCs were similarly treated as in Section Glutathione (Reduced) Assay in VSMCs and then analyzed using an ATP assay kit (Catalog No. A095-1-1, Nanjing Jiancheng Bioengineering Institute), following the manufacturer's protocol.

Western Blotting

To verify the relative expression levels of histone deacetylase 1 (HDAC1) and heterogeneous nuclear ribonucleoprotein D0 (HNRNPD) changed by •OH and 10-HDA, the Western blotting method was applied using reduced glyceraldehyde-phosphate dehydrogenase (GAPDH) and β-tubulin as internal references. The VSMCs were sampled the same as that in the proteomic analysis, and they were homogenized in the RIPA buffer (Beijing Solarbio Science & Technology) with 1% phenylmethylsulfonyl fluoride (the protease inhibitor) on ice for 20 min. After centrifugation at 13,000 rpm for 10 min, the proteins contained in the supernatants were obtained and denatured at 95°C for 5 min with 5× loading buffer. For detecting HDAC1, the concentrations of spacer gel and separation gel for electrophoresis were 5 and 12%, respectively. For HNRNPD, those were 4 and 9%, respectively. The proteins were then transferred to the nitrocellulose (NC) membrane under 110 mA for 180 min (i.e., HDAC1 and HNRNPD) or 150 min (i.e., GAPDH and β-tubulin). The NC membrane was blocked in the phosphate-buffered solution with 0.05% Tween-20 (PBST) with



5% fat-free milk for 1 h, followed by the incubation of the primary antibody against HDAC1 (Proteintech Group, Inc., Rosemont, IL, USA), HNRNP (Proteintech Group, Inc., Rosemont, IL, USA), GAPDH (Sigma-Aldrich Corp., St Louis, MO, USA), or β -tubulin (Abbkine Scientific Co., Ltd., Wuhan, Hubei, China) in PBST overnight at 4°C and the IRDye[®] 680RD Goat anti-rabbit or anti-mouse IgG secondary antibody (LI-COR, Inc., Lincoln, NE, USA) in PBST containing 5% fat-free milk for 1 h at room temperature. The bands were visualized using the Odyssey[®] CLx Imaging System (LI-COR, Inc., Lincoln, NE, USA), and the band intensities were quantified using the ImageJ software.

Statistical Analysis

Apart from the proteomic and bioinformatic statistics, the experimental data were represented by the mean \pm standard deviation (SD) based on at least three independent trials. One-way ANOVA was used to test pairwise differences in the scavenging rate of \bullet OH. The Student's *t*-test was used to determine the differences between the control and the \bullet OH-damaged VSMCs, or the \bullet OH-damaged and the \bullet OH + 10-HDA-supplemented VSMCs, in which, $P < 0.05$ was significant.


RESULTS

10-HDA Scavenges \bullet OH via a Series of Oxidation Reactions

To test whether 10-HDA is capable of eliminating \bullet OH, the scavenging rate of \bullet OH was assayed using a 10-HDA solution (2%). The scavenging rate was more than 20%, significantly higher than that of the control ($P < 0.01$) based on the

Fenton/1,10-phenanthroline monohydrate method, indicating that 10-HDA can remove \bullet OH from the solution. Compared with the positive control (i.e., 2% vitamin E), the scavenging rate of \bullet OH by 10-HDA was slightly higher, but the difference was statistically insignificant ($P > 0.05$) (Figure 1A). The second assay approach using the Fenton/Griess reagent also showed that 10-HDA had a significantly higher scavenging ability for \bullet OH than the control ($P < 0.001$) (Supplementary Figure S1). In the HPLC analysis, a single peak (Figure 1B) generated by 10-HDA confirmed that the solution was free of \bullet OH. However, the presence of a string of additional peaks (Figure 1C) indicated new products that may be due to the addition of \bullet OH to 10-HDA. Taken together, 10-HDA could scavenge \bullet OH, which may be the result of their direct reaction.

To further unravel the mechanism of the 10-HDA and \bullet OH reaction, UHPLC-HRMS was used to identify the products after the addition of \bullet OH to the 10-HDA solution. Both the 10-HDA and the \bullet OH + 10-HDA samples had chromatographic peaks for 10-HDA (retention time (RT) at 4.93 and 4.91 min, respectively) (Figure 2A), in which the MS base peaks at $m/z = 185.1181$ and 185.1182 in the negative ion mode were implicated (Supplementary Figure S2A). Compared with the chromatogram of the 10-HDA sample without \bullet OH, a string of peaks emerged after 10-HDA was treated with \bullet OH, indicating potentially derived substances (Figure 2A). Within these extra chromatographic peaks, the MS base peaks at $m/z = 183.1026$ (RT at 4.39 min), 217.1445 (RT at 4.20 and 4.58 min), and 219.1236 (RT at 3.34 min) represented the major predicted oxidized products (Supplementary Figure S2B), with the possible molecular formulas $C_{10}H_{16}O_3$ (the oxidation of the



hydroxyl group ($-\text{OH}$) to a carbonyl group ($\text{C}=\text{O}$)), C₁₀H₁₈O₅ (the oxidation of $-\text{OH}$ to a carboxyl group ($-\text{COOH}$) and the hydroxylation of the double-double carbon bond ($\text{C}=\text{C}$) or the oxidation of $-\text{OH}$ to $\text{C}=\text{O}$ and the dihydroxylation of $\text{C}=\text{C}$), and C₁₀H₂₀O₅ (the dihydroxylation of $\text{C}=\text{C}$), respectively (**Figure 2B**). Therefore, 10-HDA may undergo a series of oxidation reactions to scavenge \bullet OH.

10-HDA Protected VSMC Viability Against \bullet OH Toxicity

To uncover whether 10-HDA rescues \bullet OH-induced VSMC damage, the VSMC morphology was analyzed. Compared with the controls, the cellular shape of the VSMCs with \bullet OH treatment was destroyed. With 10-HDA supplementation, the deformation of VSMCs was alleviated (**Figure 3A**). Furthermore, using an MTT assay, the significantly reduced VSMC viability

by \bullet OH ($P < 0.001$) was significantly recovered by 10-HDA ($P < 0.01$) (**Figure 3B**). In addition, the MDA level in the VSMC supernatant was significantly increased with an \bullet OH challenge ($P < 0.001$), suggesting that lipid peroxidation of VSMCs occurred and was released from the cells; this effect was significantly reduced by 10-HDA ($P < 0.05$) (**Figure 3C**). Similarly, the MDA content within VSMCs was also significantly enhanced by \bullet OH ($P < 0.05$) and significantly reduced with the addition of 10-HDA ($P < 0.05$) (**Supplementary Figure S3**). The results demonstrate that 10-HDA maintained VSMC viability against \bullet OH toxicity, which may be the result of the inhibitory effect of 10-HDA on lipid peroxidation of VSMCs. Notably, the reduced glutathione in VSMCs was significantly lessened under the oxidative stress of \bullet OH ($P < 0.001$), which was significantly recovered by 10-HDA ($P < 0.05$) (**Figure 3D**), indicating that 10-HDA may relieve oxidative stress in blood vessels.




FIGURE 3 | 10-Hydroxydec-2-enoic acid (10-HDA) attenuates \bullet OH-induced damage in vascular smooth muscle cells (VSMCs). **(A)** The morphological comparison between the control, \bullet OH-damaged (0.1 mM $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$ + 1 mM H_2O_2), and 10-HDA-supplemented (3 mM) VSMCs. **(B)** The viabilities of \bullet OH-damaged and 10-HDA-treated VSMCs compared with that of the control using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay ($n = 6$, $**P < 0.01$, $***P < 0.001$). **(C)** The malondialdehyde (MDA) levels in the media, indicating the degrees of VSMC lipid peroxidation ($n = 5$, $*P < 0.05$, $***P < 0.001$). **(D)** The comparison of glutathione (reduced) content after VSMCs was treated by \bullet OH or \bullet OH + 10-HDA ($n = 5$, $*P < 0.05$, $***P < 0.001$). The data are shown as mean \pm standard deviation (SD).


10-HDA Restored the VSMC Proteome Altered by \bullet OH Challenge

To further explore the role of 10-HDA in protecting VSMC viability at the molecular level, the differentially expressed proteins regulated by \bullet OH and 10-HDA were compared. In total, 3,401, 2,883, and 3,467 proteins were identified in the control, \bullet OH-damaged, and 10-HDA-supplemented VSMCs, respectively. Compared with the proteins in controls, 337 proteins were significantly downregulated, and 148 proteins were significantly upregulated in the \bullet OH-damaged VSMCs (Figure 4A and Supplementary Table S1). However, with the addition of 10-HDA to the \bullet OH-damaged VSMCs, 121 proteins were significantly downregulated, and 389 proteins were significantly upregulated (Figure 4B and Supplementary Table S2). Notably, 195 proteins downregulated by \bullet OH were upregulated with 10-HDA treatment (Figure 4C), whereas only 39 proteins upregulated by \bullet OH were downregulated by 10-HDA treatment (Figure 4D).

Therefore, 10-HDA may restore the expression of a wide spectrum of proteins that were suppressed by \bullet OH.

10-HDA Reduced \bullet OH-Induced Cytotoxicity by Elevating Protein and Energy Metabolism

To reveal the biological functions of the VSMC differentially expressed proteins influenced by \bullet OH and 10-HDA, 195 proteins were analyzed for GO term and KEGG pathway enrichment. As a result, 54 items were significantly enriched across the following categories, namely, 14 in GO biological process (BP), 21 in GO cellular component (CC), 10 in GO molecular function (MF), and 9 in KEGG pathways (Supplementary Table S3). The GO terms and KEGG pathways with $P < 0.01$ are primarily involved in protein and energy metabolism, such as translation, protein transport, ribosome, RNA binding, proteasomal protein catabolic processes, fatty acid degradation, and glycolysis/gluconeogenesis (Figure 5). Hence, 10-HDA may



rescue protein and energy metabolism pathways to safeguard VSMC viability when resisting \bullet OH toxicity. The capability of 10-HDA to reverse energy production was evidenced by the significantly decreased ATP levels in VSMCs under \bullet OH stress ($P < 0.01$), which was significantly increased with supplemental 10-HDA ($P < 0.05$) (Supplementary Figure S4). However, the 39 proteins upregulated by \bullet OH and downregulated by 10-HDA were only enriched in four GO terms (NADP metabolic process, RNA binding, poly(A) + mRNA export from the nucleus, and nuclear inclusion body), and none of the KEGG pathways (Supplementary Figure S5).


10-HDA-Rescued VSMC Proteins Were Mainly Located in the Nucleus, Cytoplasm, and Mitochondrion

To establish the functional connections between VSMC proteins that were impacted by \bullet OH but recovered by 10-HDA, and to identify key node proteins, a PPI network was constructed. The 195 proteins generated 18 subnetworks, including a “continent” (i.e., subnetwork 1) (Figure 6A) and 17 “islands” (i.e., subnetworks 2–18) (Supplementary Figure S6). Subnetwork 1 had 66 seeds, 1,090 nodes, and 1,790 edges. The top 30 hub nodes (also the seeds) with their degrees are shown in Figure 6B. These

nodes with high connectivity in the PPI network may be the key proteins influenced by \bullet OH and 10-HDA. Protein subcellular localization predicted that the proteins were distributed across the cell from the cell membrane to the nucleus, particularly in the nucleus, cytoplasm, and mitochondrion (Figure 6C and Supplementary Table S4), the major locations for protein synthesis and transport and energy metabolism. Furthermore, Western blotting confirmed that HDAC1 and HNRNP (the top two hub nodes in the PPI networks) were significantly downregulated by \bullet OH and significantly upregulated *via* the supplementation of 10-HDA ($P < 0.05$) (Figure 6D), as in the proteomic analysis.

DISCUSSION

10-Hydroxydec-2-enoic acid, a unique ingredient in RJ beneficial to health, has been characterized by its ability to prevent cell damage (7–9). To unveil the mechanisms of 10-HDA's protective qualities, its role in eliminating ROS was investigated. 10-HDA demonstrated the ability to scavenge \bullet OH, the most harmful ROS, *via* direct oxidation reactions with \bullet OH. In \bullet OH-damaged mouse VSMCs, 10-HDA restored cell viability by reducing lipid peroxidation, increasing glutathione levels, and rescuing



protein and energy metabolism in the nucleus, cytoplasm, and mitochondrion. Our results shed light on the potential of 10-HDA in the prevention and treatment of vascular diseases related to \bullet OH-induced VSMC damage.

10-Hydroxydec-2-enoic acid has direct reactions with \bullet OH, which was confirmed by detecting the products after the addition of 10-HDA to the Fenton reagent. With both an $-\text{OH}$ group and a $\text{C}=\text{C}$ bond, 10-HDA can be easily oxidized. Specifically, $-\text{OH}$ can be oxidized to $\text{C}=\text{O}$ or $-\text{COOH}$, and hydroxylation of the $\text{C}=\text{C}$ bond can be catalyzed through oxidation (28, 29). According to the UHPLC-HRMS data, the molecular weights of a series of chemical compounds detected were in accordance with the molecular weights of the predicted oxidation products, indicating that 10-HDA may be oxidized to different products *via* multiple reaction steps with \bullet OH. Hence, in the presence of \bullet OH, 10-HDA can play the role of a “sponge” that absorbs oxygen atoms and therefore eliminates \bullet OH.

Since 10-HDA likely scavenges \bullet OH, this could be the molecular mechanism of 10-HDA's health-promoting functions.

A surplus of ROS is the fundamental cause of many types of cardiovascular diseases. For example, atherosclerosis can occur when the viability of VSMCs is impaired, as damage to VSMCs can lead to vascular calcification (30). Atherosclerosis is also considered a chronic inflammatory disease, in which oxidative stress due to ROS is the critical underlying factor (31). High blood pressure is closely related to abnormal VSMC contraction and relaxation, and it has been documented that oxidative stress is a common mediator underlying the pathophysiological processes of hypertension (32). Therefore, the fact that reduced VSMC viability by \bullet OH was reversed by 10-HDA implies that 10-HDA holds the potential to protect the cardiovascular system *via* the removal of \bullet OH. Hence, the intake of 10-HDA may mitigate the symptoms of atherosclerosis and hypertension. Moreover, ROS accumulation stimulated by LPS in murine macrophages is often applied as an inflammatory model (4), and LPS-induced mitochondrial ROS in cardiomyocytes is correlated with myocarditis (33, 34). Given that 10-HDA has been reported to alleviate the LPS-induced inflammation *in vitro* and *in vivo*




FIGURE 6 | 10-Hydroxydec-2-enoic acid (10-HDA) restores the expression of a set of proteins downregulated by \bullet OH that are functionally connected and broadly distributed in VSMCs. **(A)** The “continent” (Subnetwork 1) of the protein–protein interaction (PPI) network constructed by NetworkAnalyst 3.0 using the 195 proteins downregulated by \bullet OH and upregulated with 10-HDA supplementation, in which the blue dots represent the seeds (the proteins downregulated by \bullet OH and upregulated by 10-HDA treatment in VSMCs) among the nodes. The area of the dot symbolizes the degree of connectivity of the protein node in the PPI network. **(B)** The top 30 hub nodes with high degrees in subnetwork 1. **(C)** The numbers of the predicted subcellular localizations by Cell-PLoc 2.0 for the VSMC proteins downregulated by \bullet OH and upregulated by 10-HDA. **(D)** The comparisons (shown as mean \pm SD) of histone deacetylase 1 (HDAC1) and heterogeneous nuclear ribonucleoprotein D0 (HNRNP D) expressions in control, \bullet OH-damaged, and 10-HDA-supplemented VSMCs through Western blotting analysis ($n = 3$, $^*P < 0.05$).

(4, 5), our evidence of 10-HDA removing ROS suggests a role in inhibiting inflammation and inflammation-related diseases. In addition, we confirmed that 10-HDA is capable of protecting VSMC viability by inhibiting lipid peroxidation of VSMCs. Collectively, the above evidence concludes that 10-HDA is a potential agent for remedying ROS-derived human illnesses.

Our proteomic results further revealed the underlying mechanism of 10-HDA against \bullet OH toxicity in VSMCs. First, the abnormal expression and degradation of cellular proteins driven by \bullet OH were remedied by 10-HDA. In this study, within the GO terms and KEGG pathways enriched by the 195 proteins that were upregulated by 10-HDA against \bullet OH, a cascade of processes involved in protein metabolism were

included, such as translation, protein transport, ribosome, and RNA binding, which are essential for cellular protein production. This suggests that protein synthesis disrupted by ROS could be reversed by 10-HDA (35). ROS impairs proteasome function, which is essential in the removal of oxidized proteins to maintain normal cellular behavior (36); proteasome dysfunction results in proteome instability (37). Therefore, the \bullet OH-induced proteasomal suppression could impair cellular viability. In this study, multiple pathways of protein degradation were enriched, including the following GO terms: proteasomal protein catabolic process, proteasomal ubiquitin-independent protein catabolic process, proteasome complex, and proteasome, indicating that the impairment caused by \bullet OH on regular protein degradation

in VSMCs could be mitigated by 10-HDA. In addition, the proteins downregulated by 10-HDA in the •OH-damaged VSMCs were enriched in the GO term poly(A) + mRNA export from the nucleus, a process that promotes nuclear RNA decay (38). Therefore, 10-HDA might prevent •OH-induced RNA destruction in VSMCs. All this evidence suggests that 10-HDA can reduce the adverse effect of •OH *via* multiple pathways.

Second, the energy production inhibited by •OH was restored by 10-HDA. Carbohydrates are fundamental for generating ATP for cell survival and growth (39). In this study, the enriched glycolysis/gluconeogenesis pathway indicates that the treatment of •OH may disrupt the glycolytic process in VSMCs. Fatty acids are another important source of energy *via* multiple steps of metabolism (40). The significantly enriched fatty acid degradation pathway in the current data also suggests the impairment of the energy supply by oxidative damage. Our results established that the decreased intracellular ATP levels of VSMCs by •OH due to these impairments can be reversed by 10-HDA supplementation. Notably, the concept that aerobic glycolysis and fatty acid oxidation metabolic pathways in VSMCs are crucial to functional vasculature is broadly accepted (41); thus, 10-HDA is a promising treatment for VSMC-related vascular diseases.

Third, a large number of the 10-HDA upregulated proteins mainly function in the cell nucleus, cytoplasm, mitochondrion, and endoplasmic reticulum. 10-HDA-rescued proteins were found widely distributed within VSMCs from the cell membrane, throughout the cytoplasm, and in the nucleus, indicating that 10-HDA could provide broad protection against •OH damage at the molecular level. However, most of these proteins were located in the nucleus and cytoplasm, which is logical because the key impact of ROS is nuclear DNA fragmentation and chromatin dysfunction (42). Therefore, one of the major effects of 10-HDA in VSMCs is to protect the nuclear and cytoplasmic proteins, which is also reflected by the PPI results in which more than 90% of the top 30 hub nodes were predicted to locate in the nucleus and cytoplasm. Moreover, the enrichment in the mitochondrion and endoplasmic reticulum further supports the fact that protecting protein and energy metabolism are major mechanisms through which 10-HDA reduces •OH toxicity. In addition, our PPI results also provide vital target proteins involved in 10-HDA's amelioration of vascular abnormality. Of the top two hub nodes with degree >110, HDAC1 can increase VSMC viability and migration under quiescent conditions (43). Although the knowledge of the role of HNRNP in VSMCs is very limited, HNRNP family members are shown to be important modulators of VSMC functions (44, 45). Therefore, HDAC1 and HNRNP may be the crucial intracellular molecules associated with 10-HDA's restoration of VSMC survival.

CONCLUSION

In conclusion, this work provides concrete evidence that 10-HDA, a unique RJ component, has a biological function in scavenging •OH *via* oxidative reactions. Using •OH-damaged mouse VSMCs as a model, we confirmed the function of 10-HDA

in protecting VSMC viability against •OH-induced cytotoxicity. Specifically, the cytoprotective mechanism of 10-HDA against •OH is believed to restore protein and energy metabolism within the nucleus, cytoplasm, and mitochondrion. Our results shed light on the novel potential of 10-HDA in the prevention and treatment of cardiovascular diseases in human.

DATA AVAILABILITY STATEMENT

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/**Supplementary Material**. The data sets (MS proteomic raw data) for this study can be found in the ProteomeXchange Consortium (<http://proteomecentral.proteomexchange.org>) with the dataset identifier IPX0003749001.

AUTHOR CONTRIBUTIONS

PF: conceptualization, methodology, investigation, and writing—original draft. FS: investigation. CM: methodology and investigation. QW: investigation. YZ: investigation. JS: investigation. JF: investigation. LZ: investigation, funding acquisition, and supervision. BH: methodology, investigation, funding acquisition, and writing—review and editing. JL: project administration, funding acquisition, writing—review and editing, and supervision. All authors contributed to the article and approved the submitted version.

FUNDING

This study was supported by the open project fund from the Key Laboratory of Pollinating Insect Biology, Ministry of Agriculture and Rural Affairs, P. R. China (2018MFNZS02), the National Natural Science Foundation of China (32070742 and 31970428), the Innovative Funds Plan of Henan University of Technology (2021ZKCJ16), and the Modern Agro-Industry Technology Research System (CARS-45) in China.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fnut.2022.873892/full#supplementary-material>

Supplementary Figure S1 | 10-HDA scavenges •OH *via* Fenton/Griess reagent colorimetric assay. Unlike the Fenton/1,10-phenanthroline monohydrate-based method, it requires the ethanol-free samples according to the kit's instruction. Here, 10-HDA was dissolved in olive oil with the content of 2% (g/mL), and the same volume of olive oil without 10-HDA was the control ($n = 3$, *** $P < 0.001$).

Supplementary Figure S2 | The MS base peaks implicated in the extra chromatographic peaks emerged by the treatment of •OH to 10-HDA. **(A)** shows the MS base peak for 10-HDA without or with •OH addition. **(B)** displays the emerged MS base peaks after the reaction of •OH and 10-HDA.

Supplementary Figure S3 | 10-HDA reduces the intracellular MDA content of VSMCs, an indicator for lipid peroxidation, that are enhanced by •OH. The data were shown as mean \pm SD ($n = 4$, * $P < 0.05$).

Supplementary Figure S4 | 10-HDA boosts the intracellular ATP level in VSMCs that are inhibited by the oxidative stress from •OH (data shown as mean \pm SD with $n = 3$, ** $P < 0.01$, * $P < 0.05$).

Supplementary Figure S5 | 10-HDA may suppress the functions of NADP metabolic process, poly(A) + mRNA export from nucleus, RNA binding, and nuclear inclusion body induced by •OH in VSMCs. The items shown are the GO terms enriched by the 39 proteins that are up-regulated by •OH and down-regulated by 10-HDA. The number of the proteins implicated in the items is near each bar, and * means the corrected P -value < 0.05 . % Genes/Term, the bar length, is the ratio of input proteins to the all within a term.

Supplementary Figure S6 | The Subnetworks 2–18 of the PPI network, known as the “islands”, constructed by the VSMC proteins down-regulated by •OH and

up-regulated by 10-HDA. The seeds of the networks were shown as the blue dots among nodes. The area of the node represents its degree in the network.

Supplementary Table S1 | The differentially expressed proteins by •OH in VSMCs.

Supplementary Table S2 | The differentially expressed proteins with the addition of 10-HDA to the •OH treated VSMCs.

Supplementary Table S3 | GO term and KEGG pathway enrichment for the proteins down-regulated by •OH and up-regulated with 10-HDA treatment in VSMCs.

Supplementary Table S4 | The subcellular localization prediction for the proteins down-regulated by •OH and up-regulated by 10-HDA administration in VSMCs.

REFERENCES

- Bălan A, Moga MA, Dima L, Toma S, Neculau AE, Anastasiu CV. Royal jelly—a traditional and natural remedy for postmenopausal symptoms and aging-related pathologies. *Molecules*. (2020) 25:3291. doi: 10.3390/molecules25143291
- Yang W, Tian Y, Han M, Miao X. Longevity extension of worker honey bees (*Apis mellifera*) by royal jelly: optimal dose and active ingredient. *Peer J*. (2017) 5:e3118. doi: 10.7717/peerj.3118
- Fratini F, Cilia G, Mancini S, Felicioli A. Royal jelly: an ancient remedy with remarkable antibacterial properties. *Microbiol Res*. (2016) 192:130–41. doi: 10.1016/j.micres.2016.06.007
- Chen Y, Wang K, Zhang Y, Zheng Y, Hu F. *In vitro* anti-inflammatory effects of three fatty acids from royal jelly. *Mediators Inflamm*. (2016) 2016:3583684. doi: 10.1155/2016/3583684
- You M, Miao Z, Tian J, Hu F. Trans-10-hydroxy-2-decenoic acid protects against LPS-induced neuroinflammation through FOXO1-mediated activation of autophagy. *Eur J Nutr*. (2020) 59:2875–92. doi: 10.1007/s00394-019-02128-9
- Filipič B, Gradišnik L, Rihar K, Šooš E, Pereyra A, Potokar J. The influence of royal jelly and human interferon- α (HuIFN- α N3) on proliferation, glutathione level and lipid peroxidation in human colorectal adenocarcinoma cells *in vitro*. *Arh Hig Rada Toksikol*. (2015) 66:269–74. doi: 10.1515/aiht-2015-66-2632
- Zheng J, Lai W, Zhu G, Wan M, Chen J, Tai Y, et al. 10-Hydroxy-2-decenoic acid prevents ultraviolet A-induced damage and matrix metalloproteinases expression in human dermal fibroblasts. *J Eur Acad Dermatol Venereol*. (2013) 27:1269–77. doi: 10.1111/j.1468-3083.2012.04707.x
- You M, Miao Z, Pan Y, Hu F. Trans-10-hydroxy-2-decenoic acid alleviates LPS-induced blood-brain barrier dysfunction by activating the AMPK/PI3K/AKT pathway. *Eur J Pharmacol*. (2019) 865:172736. doi: 10.1016/j.ejphar.2019.172736
- Fan P, Han B, Hu H, Wei Q, Zhang X, Meng L, et al. Proteome of thymus and spleen reveals that 10-hydroxydec-2-enoic acid could enhance immunity in mice. *Expert Opin Ther Targets* (2020) 24:267–79. doi: 10.1080/14728222.2020.1733529
- Davalli P, Mitic T, Caporali A, Lauriola A, D'Arca D. ROS, cell senescence, and novel molecular mechanisms in aging and age-related diseases. *Oxid Med Cell Longev*. (2016) 2016:3565127. doi: 10.1155/2016/3565127
- Valko M, Jomova K, Rhodes CJ, Kuča K, Musilek K. Redox- and non-redox-metal-induced formation of free radicals and their role in human disease. *Arch Toxicol*. (2016) 90:1–37. doi: 10.1007/s00204-015-1579-5
- Liu F, Li X, Lin T, He D, Wei G, Liu J, et al. The cyclophosphamide metabolite, acrolein, induces cytoskeletal changes and oxidative stress in Sertoli cells. *Mol Biol Rep*. (2012) 39:493–500. doi: 10.1007/s11033-011-0763-9
- Catapano AL. Antioxidant effect of flavonoids. *Angiology*. (1997) 48:39–44. doi: 10.1177/000331979704800107
- Richards SL, Wilkins KA, Swarbreck SM, Anderson AA, Habib N, Smith AG, et al. The hydroxyl radical in plants: from seed to seed. *J Exp Bot*. (2015) 66:37–46. doi: 10.1093/jxb/eru398
- Park S, Kim N, Yang W, Nah J, Jang M, Lee D. Polymeric micellar nanoplateforms for Fenton reaction as a new class of antibacterial agents. *J Control Release*. (2016) 221:37–47. doi: 10.1016/j.jconrel.2015.11.027
- Zou Y, Chen Z, Jennings B, Zhao G, Gu Q, Bhattacharya A, et al. Deletion of DGCR8 in VSMCs of adult mice results in loss of vascular reactivity, reduced blood pressure and neointima formation. *Sci Rep*. (2018) 8:1468. doi: 10.1038/s41598-018-19660-z
- Badran A, Nasser SA, Mesmar J, El-Yazbi AF, Bitto A, Fardoun MM, et al. Reactive oxygen species: modulators of phenotypic switch of vascular smooth muscle cells. *Int J Mol Sci*. (2020) 21:8764. doi: 10.3390/ijms21228764
- Li PF, Dietz R, von Harsdorf R. Differential effect of hydrogen peroxide and superoxide anion on apoptosis and proliferation of vascular smooth muscle cells. *Circulation*. (1997) 96:3602–9. doi: 10.1161/01.CIR.96.10.3602
- Qiu X, Takemura G, Koshiji M, Hayakawa Y, Kanoh M, Maruyama R, et al. Gallic acid induces vascular smooth muscle cell death via hydroxyl radical production. *Heart Vessels*. (2000) 15:90–9. doi: 10.1007/s003800070038
- Korany MA, Moneeb MS, Asaad AM, El-Sebakhy NA, El-Banna AA. A validated stability-indicating HPTLC assay for determination of 10-hydroxy-2-decenoic acid content in royal jelly products using robust regression methods. *J Chromatogr Sci*. (2020) 58:520–34. doi: 10.1093/chromsci/bmaa016
- Ma C, Zhang L, Feng M, Fang Y, Hu H, Han B, et al. Metabolic profiling unravels the effects of enhanced output and harvesting time on royal jelly quality. *Food Res Int*. (2021) 139:109974. doi: 10.1016/j.foodres.2020.109974
- Sugiyama T, Takahashi K, Tokoro S, Gotou T, Neri P, Mori H. Inhibitory effect of 10-hydroxy-trans-2-decenoic acid on LPS-induced IL-6 production via reducing I κ B- ζ expression. *Innate Immun*. (2012) 18:429–37. doi: 10.1177/1753425911416022
- Fan P, Han B, Feng M, Fang Y, Zhang L, Hu H, et al. Functional and proteomic investigations reveal major royal jelly protein 1 associated with anti-hypertension activity in mouse vascular smooth muscle cells. *Sci Rep*. (2016) 6:30230. doi: 10.1038/srep30230
- Han B, Wei Q, Wu F, Hu H, Ma C, Meng L, et al. Tachykinin signaling inhibits task-specific behavioral responsiveness in honeybee workers. *eLife*. (2021) 10:e64830. doi: 10.7554/eLife.64830
- Bu D, Luo H, Huo P, Wang Z, Zhang S, He Z, et al. KOBAS-i: intelligent prioritization and exploratory visualization of biological functions for gene enrichment analysis. *Nucleic Acids Res*. (2021) 49:W317–25. doi: 10.1093/nar/gkab447
- Zhou G, Soufan O, Ewald J, Hancock REW, Basu N, Xia J. NetworkAnalyst 30: a visual analytics platform for comprehensive gene expression profiling and meta-analysis. *Nucleic Acids Res*. (2019) 47:W234–41. doi: 10.1093/nar/gkz240
- Chou K, Shen H. A new method for predicting the subcellular localization of eukaryotic proteins with both single and multiple sites: Euk-mPLoc 20. *PLoS ONE*. (2010) 5:e9931. doi: 10.1371/journal.pone.0009931
- Hoover JM, Stahl SS. Highly practical copper(I)/TEMPO catalyst system for chemoselective aerobic oxidation of primary alcohols. *J Am Chem Soc*. (2011) 133:16901–10. doi: 10.1021/ja206230h
- Sugimoto H, Kitayama K, Mori S, Itoh S. An osmium (III)/osmium (V) redox couple generating OsV(O)(OH) center for cis-1,2-dihydroxylation of alkenes with H₂O₂: Os complex with a nitrogen-based tetradentate ligand. *J Am Chem Soc*. (2012) 134:19270–80. doi: 10.1021/ja309566c

30. Shin M, Kwun I. Zinc restored the decreased vascular smooth muscle cell viability under atherosclerotic calcification conditions. *Prev Nutr Food Sci.* (2014) 19:363–6. doi: 10.3746/pnf.2014.19.4.363
31. Kattoor AJ, Pothineni NVK, Palagiri D, Mehta JL. Oxidative stress in atherosclerosis. *Curr Atheroscler Rep.* (2017) 19:42. doi: 10.1007/s11883-017-0678-6
32. Touyz RM, Rios FJ, Alves-Lopes R, Neves KB, Camargo LL, Montezano AC. Oxidative stress: a unifying paradigm in hypertension. *Can J Cardiol.* (2020) 36:659–70. doi: 10.1016/j.cjca.2020.02.081
33. Tada Y, Suzuki J. Oxidative stress and myocarditis. *Curr Pharm Des.* (2016) 22:450–71. doi: 10.2174/1381612822666151222160559
34. Li Y, Feng Y, Liu X, Li Y, Zhu H, Sun M, et al. Songorine promotes cardiac mitochondrial biogenesis via Nrf2 induction during sepsis. *Redox Biol.* (2021) 38:101771. doi: 10.1016/j.redox.2020.101771
35. Ghosh A, Shcherbik N. Effects of oxidative stress on protein translation: implications for cardiovascular diseases. *Int J Mol Sci.* (2020) 21:2661. doi: 10.3390/ijms21082661
36. Torres CA, Perez VI. Proteasome modulates mitochondrial function during cellular senescence. *Free Radic Biol Med.* (2008) 44:403–14. doi: 10.1016/j.freeradbiomed.2007.10.002
37. Tsakiri EN, Gumeni S, Vougas K, Pendin D, Papassideri I, Daga A, et al. Proteasome dysfunction induces excessive proteome instability and loss of mitostasis that can be mitigated by enhancing mitochondrial fusion or autophagy. *Autophagy.* (2019) 15:1757–73. doi: 10.1080/15548627.2019.1596477
38. Bresson SM, Hunter OV, Hunter AC, Conrad NK. Canonical Poly(A) polymerase activity promotes the decay of a wide variety of mammalian nuclear RNAs. *PLoS Genet.* (2015) 11:e1005610. doi: 10.1371/journal.pgen.1005610
39. Karwi QG, Jörg AR, Lopaschuk GD. Allosteric, transcriptional and post-translational control of mitochondrial energy metabolism. *Biochem J.* (2019) 476:1695–712. doi: 10.1042/BCJ20180617
40. de Carvalho CCR, Caramujo MJ. The various roles of fatty acids. *Molecules.* (2018) 23:2583. doi: 10.3390/molecules23102583
41. Shi J, Yang Y, Cheng A, Xu G, He F. Metabolism of vascular smooth muscle cells in vascular diseases. *Am J Physiol Heart Circ Physiol.* (2020) 319:H613–31. doi: 10.1152/ajpheart.00220.2020
42. Higuchi Y. Chromosomal DNA fragmentation in apoptosis and necrosis induced by oxidative stress. *Biochem Pharmacol.* (2003) 66:1527–35. doi: 10.1016/S0006-2952(03)00508-2
43. Sun L, Wang C, Yuan Y, Guo Z, He Y, Ma W, et al. Downregulation of HDAC1 suppresses media degeneration by inhibiting the migration and phenotypic switch of aortic vascular smooth muscle cells in aortic dissection. *J Cell Physiol.* (2020) 235:8747–56. doi: 10.1002/jcp.29718
44. Zhang L, Chen Q, An W, Yang F, Maguire EM, Chen D, et al. Novel pathological role of hnRNPA1 (heterogeneous nuclear ribonucleoprotein A1) in vascular smooth muscle cell function and neointima hyperplasia. *Arterioscler Thromb Vasc Biol.* (2017) 37:2182–94. doi: 10.1161/ATVBAHA.117.310020
45. Zhang R, Wu C, Hu X, Lin X, Hua Y, Chen J, et al. LncRNA AC1059421 downregulates hnRNPA2/B1 to attenuate vascular smooth muscle cells proliferation. *DNA Cell Biol.* (2021) 40:652–61. doi: 10.1089/dna.2020.6451

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Fan, Sha, Ma, Wei, Zhou, Shi, Fu, Zhang, Han and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.